Online searches for hepatocellular carcinoma drugs mirror prescription trends across specialties and changes in guideline recommendations Journal Article
| Authors: | Berning, P.; Schroer, A. E.; Adhikari, R.; Razavi, A. C.; Cornelis, F. H.; Erinjeri, J. P.; Solomon, S. B.; Sarkar, D.; Vargas, H. A.; Schöder, H.; Fox, J. J.; Dzaye, O. |
| Article Title: | Online searches for hepatocellular carcinoma drugs mirror prescription trends across specialties and changes in guideline recommendations |
| Abstract: | Background & aims: The treatment options for systemically progressed hepatocellular carcinoma (HCC) have significantly expanded in recent years. In this study, we aimed to evaluate the potential of Google searches as a reflection of prescription rates for HCC drugs in the United States (US). Methods: We conducted an in-depth analysis of US prescription data obtained from the IQVIA National Prescription Audit (NPA) and corresponding Google Trends data from January 2017 to December 2022. We focused on drugs used in the first line and second or later treatment lines for HCC, collecting data on their prescriptions and search rates. Search volumes were collected as aggregated search queries for both generic drugs and their respective brand names. Results: During the study period from Q1 2017 to Q4 2022, monthly prescriptions for drugs used in HCC treatment showed an 173% increase (from 1253 to 3422). Conversely online searches increased by 3.5% (from 173 to 179 per 10 million searches). Notably, strong correlations were observed between search interest and prescriptions for newer drugs, which indicates increasing usage, while older drugs with declining usage displayed limited correlation. Our findings suggest a growing role of non-physician professions in managing systemically progressed HCC within the US healthcare system, although oncologists remained primarily responsible for drug prescriptions. Conclusions: In conclusion, online search monitoring can offer the potential to reflect prescription trends specifically related to the treatment of HCC. This approach provides a swift and accessible means of evaluating the evolving landscape of HCC treatment. Copyright © 2024 Berning, Schroer, Adhikari, Razavi, Cornelis, Erinjeri, Solomon, Sarkar, Vargas, Schöder, Fox and Dzaye. |
| Keywords: | hepatocellular carcinoma; sorafenib; cabozantinib; lenvatinib; google trends |
| Journal Title: | Frontiers in Oncology |
| Volume: | 14 |
| ISSN: | 2234-943X |
| Publisher: | Frontiers Media S.A. |
| Date Published: | 2024-01-01 |
| Start Page: | 1324095 |
| Language: | English |
| DOI: | 10.3389/fonc.2024.1324095 |
| PROVIDER: | scopus |
| PMCID: | PMC10884243 |
| PUBMED: | 38406802 |
| DOI/URL: | |
| Notes: | Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work